1425822-40-7

Upstream product

• 1425822-34-9 ethyl 3-[2-(benzyloxy)ethoxy]-4-iodobenzoate 
• 1425822-37-2 (S)-ethyl 4-[8-amino-1,2,4,5-tetrahydro-2-(2-methylpropyl)-4-(3-methylbutyl)-3-oxo-3H-1,4-benzodiazepin-7-yl]-3-[2-(benzyloxy)ethoxy]benzoate 
• 36282-26-5 2-bromo-4-fluorobenzonitrile 
• 1220099-39-7 2-bromo-4-(4-methoxybenzylamino)benzonitrile 
• 53312-82-6 4-amino-2-bromobenzonitrile 
• 203187-56-8 4-iodo-3-hydroxybenzoic acid ethyl ester 
• 7781-98-8 ethyl-3-hydroxybenzoate 
• 1425822-26-9 C₁₈H₂₈IN₃O 
• 1429230-67-0 C₂₄H₃₁BO₆ 
• 1425822-24-7 C₁₈H₂₉N₃O 
• 1425822-22-5 (S)-8-bis(tert-butoxycarbonyl)amino-1,2,4,5-tetrahydro-4-(3-methylbutyl)-2-(2-methylpropyl)-3H-1,4-benzodiazepin-3-one 
• 1425822-20-3 (S)-8-bis(tert-butoxycarbonyl)amino-1,2,4,5-tetrahydro-4-(3-methylbut-2-enyl)-2-(2-methylpropyl)-3H-1,4-benzodiazepin-3-one 
• 1425822-18-9 (S)-8-bis(tert-butoxycarbonyl)amino-1,2,4,5-tetrahydro-2-(2-methylpropyl)-3H-1,4-benzodiazepin-3-one 
• 1425822-16-7 (S)-methyl 2-(5-(bis(tert-butoxycarbonyl)amino)-2-cyanophenylamino)-4-methylpentanoate 

Relevant academic research and scientific papers

Structure-activity relationship of benzodiazepine derivatives as LXXLL peptide mimetics that inhibit the interaction of vitamin D receptor with coactivators

Suppression of vitamin D receptor (VDR)-mediated transcription is expected to be of therapeutic value in Paget's disease of bone. It is known that interaction between VDR and coactivators is necessary for VDR transactivation, and the interaction occurs wh